Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$233 Mln
P/E Ratio
--
P/B Ratio
0.81
Industry P/E
--
Debt to Equity
0.01
ROE
-0.16 %
ROCE
16.2 %
Div. Yield
0 %
Book Value
7.13
EPS
1.14
CFO
$--
EBITDA
$--
Net Profit
$--
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
TF Financial Corp (THRD)
| -49.95 | 47.14 | -11.82 | -55.79 | -- | -- | -- |
|
BSE Sensex*
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
TF Financial Corp (THRD)
| -6.15 | 155.12 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell... surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California. Address: 1700 Montgomery Street, San Francisco, CA, United States, 94111 Read more
CEO & Director
Ms. Natalie C. Holles
CEO & Director
Ms. Natalie C. Holles
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of TF Financial Corp (THRD) stood at $ 295 Mln as on 31-Dec-24
The share price of TF Financial Corp (THRD) is $5.15 (NASDAQ) as of 23-Apr-2025 16:01 EDT. TF Financial Corp (THRD) has given a return of -55.79% in the last 1 years.
TF Financial Corp (THRD) has a market capitalisation of $ 233 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of TF Financial Corp (THRD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the TF Financial Corp (THRD) and enter the required number of quantities and click on buy to purchase the shares of TF Financial Corp (THRD).
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California. Address: 1700 Montgomery Street, San Francisco, CA, United States, 94111
The CEO & director of Ms. Natalie C. Holles. is TF Financial Corp (THRD), and CFO & Sr. VP is Ms. Natalie C. Holles.
There is no promoter pledging in TF Financial Corp (THRD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| TF Financial Corp (THRD) | Ratios |
|---|---|
|
Return on equity(%)
|
16.41
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of TF Financial Corp (THRD) was $0 Mln.
$-0.01
(
